Valuation: Genmab A/S

Market Cap 218B 32.22B 29.2B 27B 24.37B 45.92B 3,038B 47.54B 324B 129B 1,623B 121B 118B 5,151B P/E 2026 *
40.6x
P/E 2027 * 31.7x
Enterprise Value 237B 35.01B 31.73B 29.35B 26.48B 49.9B 3,301B 51.66B 353B 140B 1,764B 131B 129B 5,598B EV / Sales 2026 *
7.91x
EV / Sales 2027 * 6.35x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-2.32%
1 week-2.24%
Current month-11.86%
1 month+36.34%
3 months+70.10%
6 months+104.75%
Current year+70.10%
1 week 3,423
Extreme 3423
3,728
1 month 2,473
Extreme 2473
3,947
Current year 1,512
Extreme 1512
3,947
1 year 1,512
Extreme 1512
3,947
3 years 1,157
Extreme 1157
3,947
5 years 1,157
Extreme 1157
3,947
10 years 786.2
Extreme 786.2
3,947
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

189 0.0003%
12/1/25 A Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-2.32%-2.24%+76.50%+56.02% 32.22B
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+93.22% 60.62B
0.00%+0.39%+22.34%+89.58% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+2.62%+5.90%-37.29%+386.59% 26.58B
-4.38%-1.85%+40.28%-7.81% 24.45B
Average -0.99%-0.14%+37.14%+158.54% 43B
Weighted average by Cap. -1.03%+0.08%+36.84%+143.79%

Financials

2026 *2027 *
Net sales 29.98B 4.43B 4.01B 3.71B 3.35B 6.31B 417B 6.53B 44.56B 17.67B 223B 16.61B 16.25B 708B 36.28B 5.36B 4.85B 4.49B 4.05B 7.63B 505B 7.9B 53.93B 21.38B 270B 20.1B 19.67B 856B
Net income 5.36B 791M 717M 663M 598M 1.13B 74.56B 1.17B 7.96B 3.16B 39.83B 2.97B 2.9B 126B 7.12B 1.05B 952M 880M 794M 1.5B 99.04B 1.55B 10.58B 4.19B 52.91B 3.94B 3.86B 168B
Net Debt 18.93B 2.8B 2.53B 2.34B 2.11B 3.98B 264B 4.12B 28.14B 11.16B 141B 10.49B 10.27B 447B 12.27B 1.81B 1.64B 1.52B 1.37B 2.58B 171B 2.67B 18.24B 7.23B 91.25B 6.8B 6.65B 290B
Projected Income Statement - Annual - Genmab A/S
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,244
Date Price Change Volume
13/11/26 DKK 3,448.00 -2.32% 130,080
12/11/26 DKK 3,530.00 -0.87% 276,750
11/11/26 DKK 3,561.00 -0.56% 201,425
10/11/26 DKK 3,581.00 -2.19% 129,461
09/11/26 DKK 3,661.00 +3.80% 141,775
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Genmab A/S
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,448.00DKK
Average target price
4,056.77DKK
Spread / Average Target
+17.66%
  1. Stock Market
  2. Stocks
  3. GMAB Stock